|
Market Report: GlaxoSmithKline stays healthy on asthma news
The Independent There have been concerns the group's major asthma product could be knocked by generic versions being produced, but Goldman Sachs said it now appeared likely a rival drug by Sandoz would be delayed. As a result, scribblers from the broker said they … |
View full post on asthma – Google News